{
    "hands_on_practices": [
        {
            "introduction": "Understanding Hemolytic Disease of the Newborn (HDN) begins with assessing risk, which is rooted in genetics. This exercise moves beyond a simple understanding of Mendelian inheritance to a quantitative risk assessment using principles of population genetics. By applying the Hardy-Weinberg equilibrium, you can calculate the probability of an at-risk pregnancy even when some genetic information, like the father's exact genotype, is unknown, a common scenario in clinical practice .",
            "id": "4379605",
            "problem": "An RhD-negative pregnant patient is at risk for Hemolytic Disease of the Newborn (HDN) if the fetus expresses the Rhesus D antigen. Assume the RhD locus is biallelic with a dominant allele $D$ conferring RhD-positive phenotype and a recessive allele $d$ conferring RhD-negative phenotype. The mother is confirmed to be RhD-negative with genotype $dd$. The father is RhD-positive by serology, but his zygosity (whether $DD$ or $Dd$) is unknown. Both parents are drawn from a large, randomly mating population in Hardy–Weinberg Equilibrium (HWE). Let $p$ denote the frequency of the $D$ allele and $q$ denote the frequency of the $d$ allele in the population, with $p + q = 1$. In HWE, the genotype frequencies are $p^{2}$ for $DD$, $2pq$ for $Dd$, and $q^{2}$ for $dd$. The RhD-positive phenotype corresponds to genotypes $DD$ and $Dd$.\n\nSuppose the population frequency of RhD-negative phenotype (genotype $dd$) is $q^{2} = 0.16$. Using only the definitions above, HWE assumptions, and Mendelian inheritance, compute the probability that this RhD-negative mother is carrying an RhD-positive fetus, given that the father is RhD-positive. Express your answer as a decimal rounded to four significant figures.",
            "solution": "The problem asks for the probability that an RhD-negative mother carries an RhD-positive fetus, given that the father's phenotype is RhD-positive. The population is assumed to be in Hardy–Weinberg Equilibrium (HWE). We are given the population frequency of the RhD-negative phenotype.\n\nLet $D$ be the dominant allele for the RhD-positive phenotype and $d$ be the recessive allele for the RhD-negative phenotype. The mother is RhD-negative, so her genotype is definitively $dd$. The father is RhD-positive, so his genotype is either $DD$ or $Dd$.\n\nFirst, we determine the frequencies of the alleles $D$ and $d$ in the population. Let $p$ be the frequency of allele $D$ and $q$ be the frequency of allele $d$. According to HWE, the frequency of the RhD-negative genotype, $dd$, is $q^2$.\nWe are given that the population frequency of the RhD-negative phenotype is $0.16$.\n$$q^{2} = 0.16$$\nSince $q$ represents an allele frequency, it must be a non-negative value. Therefore, we can find $q$ by taking the square root:\n$$q = \\sqrt{0.16} = 0.4$$\nThe sum of the allele frequencies must be $1$:\n$$p + q = 1$$\nSolving for $p$, we get:\n$$p = 1 - q = 1 - 0.4 = 0.6$$\nSo, the frequency of the dominant allele $D$ is $p=0.6$ and the frequency of the recessive allele $d$ is $q=0.4$.\n\nNext, we must determine the probability of the father having genotype $DD$ or $Dd$, given that he is RhD-positive. The RhD-positive phenotype corresponds to genotypes $DD$ and $Dd$. The population frequencies of these genotypes are $p^2$ for $DD$ and $2pq$ for $Dd$.\nThe probability of an individual from this population being RhD-positive is the sum of the frequencies of the genotypes that confer this phenotype:\n$$P(\\text{RhD+}) = P(DD) + P(Dd) = p^{2} + 2pq$$\nSubstituting the calculated allele frequencies:\n$$P(\\text{RhD+}) = (0.6)^{2} + 2(0.6)(0.4) = 0.36 + 0.48 = 0.84$$\nAlternatively, $P(\\text{RhD+}) = 1 - P(\\text{RhD-}) = 1 - q^2 = 1 - 0.16 = 0.84$.\n\nNow, we can find the conditional probabilities of the father's genotype using the definition of conditional probability, $P(A|B) = P(A \\cap B) / P(B)$:\nThe probability that the father's genotype is $DD$, given he is RhD-positive, is:\n$$P(\\text{father is } DD \\mid \\text{father is RhD+}) = \\frac{P(DD)}{P(\\text{RhD+})} = \\frac{p^{2}}{p^{2} + 2pq} = \\frac{0.36}{0.84}$$\nThe probability that the father's genotype is $Dd$, given he is RhD-positive, is:\n$$P(\\text{father is } Dd \\mid \\text{father is RhD+}) = \\frac{P(Dd)}{P(\\text{RhD+})} = \\frac{2pq}{p^{2} + 2pq} = \\frac{0.48}{0.84}$$\n\nThe fetus will be RhD-positive if it inherits a $D$ allele from the father, since the mother has genotype $dd$ and can only pass on a $d$ allele. The resulting genotype of an RhD-positive fetus would be $Dd$. Therefore, the probability of the fetus being RhD-positive is equal to the probability that the father passes on a $D$ allele.\n\nWe can calculate this probability using the law of total probability, conditioned on the father's possible genotypes:\n$P(\\text{Fetus is RhD+}) = P(\\text{father passes } D \\mid \\text{father is RhD+})$\nThis probability is the sum of two scenarios:\n1. The father is $DD$ and passes on a $D$ allele.\n2. The father is $Dd$ and passes on a $D$ allele.\n\n$P(\\text{fetus is RhD+}) = P(\\text{father passes } D \\mid \\text{father is } DD) \\times P(\\text{father is } DD \\mid \\text{father is RhD+}) + P(\\text{father passes } D \\mid \\text{father is } Dd) \\times P(\\text{father is } Dd \\mid \\text{father is RhD+})$\n\nAccording to Mendelian inheritance:\n- A father with genotype $DD$ will always pass on a $D$ allele, so $P(\\text{father passes } D \\mid \\text{father is } DD) = 1$.\n- A father with genotype $Dd$ will pass on a $D$ allele with a probability of $1/2$, so $P(\\text{father passes } D \\mid \\text{father is } Dd) = \\frac{1}{2}$.\n\nSubstituting these values into the equation:\n$$P(\\text{Fetus is RhD+}) = (1) \\times \\left(\\frac{p^{2}}{p^{2} + 2pq}\\right) + \\left(\\frac{1}{2}\\right) \\times \\left(\\frac{2pq}{p^{2} + 2pq}\\right)$$\n$$P(\\text{Fetus is RhD+}) = \\frac{p^{2} + pq}{p^{2} + 2pq}$$\nWe can factor $p$ from the numerator and denominator (since $p \\neq 0$):\n$$P(\\text{Fetus is RhD+}) = \\frac{p(p+q)}{p(p+2q)} = \\frac{p+q}{p+2q}$$\nSince $p+q=1$, this simplifies to:\n$$P(\\text{Fetus is RhD+}) = \\frac{1}{p+2q}$$\nAnd since $p = 1-q$, we have:\n$$P(\\text{Fetus is RhD+}) = \\frac{1}{(1-q)+2q} = \\frac{1}{1+q}$$\nUsing our calculated value of $q=0.4$:\n$$P(\\text{Fetus is RhD+}) = \\frac{1}{1+0.4} = \\frac{1}{1.4} = \\frac{10}{14} = \\frac{5}{7}$$\nTo provide the answer as a decimal rounded to four significant figures, we perform the division:\n$$\\frac{5}{7} \\approx 0.7142857...$$\nRounding to four significant figures gives $0.7143$.",
            "answer": "$$\\boxed{0.7143}$$"
        },
        {
            "introduction": "When a newborn presents with signs of hemolysis, a clinician must navigate a broad differential diagnosis. This practice challenges you to think like a pathologist by constructing a logical diagnostic algorithm to distinguish between immune and non-immune causes of hemolysis. Mastering this systematic approach, which pivots on the results of the Direct Antiglobulin Test (DAT), is fundamental to reaching an accurate and timely diagnosis in neonatal care .",
            "id": "4379597",
            "problem": "A term neonate at day $2$ of life presents with jaundice, pallor, and tachycardia. Laboratory data show anemia with elevated reticulocytes and predominantly unconjugated hyperbilirubinemia. Your task is to select the most appropriate diagnostic decision pathway that rationally separates immune from nonimmune hemolysis and then narrows the etiology using key discriminators. Use the following well-established facts as the fundamental base for your reasoning:\n- The Direct antiglobulin test (DAT, also called the direct Coombs test) detects immunoglobulin or complement bound in vivo to red blood cells (RBCs). A positive DAT indicates immune-mediated hemolysis; a negative DAT makes immune hemolysis unlikely and raises nonimmune causes.\n- Maternal anti–red cell antibodies capable of crossing the placenta are typically Immunoglobulin G (IgG). ABO incompatibility is most often seen when the mother is blood group O and the infant is group A or B, and may produce a weakly positive DAT. Rhesus D (RhD) disease requires an RhD-negative mother, an RhD-positive infant, and maternal sensitization; it often produces a strongly positive DAT and can be severe.\n- In DAT-negative hemolysis, peripheral smear patterns suggest mechanisms: spherocytes in membrane defects (for example, hereditary spherocytosis), bite or blister cells in oxidant injury (for example, glucose-6-phosphate dehydrogenase (G6PD) deficiency), schistocytes in mechanical fragmentation (for example, disseminated intravascular coagulation), and echinocytes in pyruvate kinase deficiency.\n- Enzyme deficiencies are confirmed by enzyme activity assays (for example, G6PD, pyruvate kinase), but activity assays can be falsely normal early in hemolytic crises when reticulocytosis is high.\n- When DAT is positive but ABO and RhD are compatible, minor blood group antibodies (for example, Kell, Duffy, Kidd) should be considered using elution testing and maternal antibody screening.\n\nWhich of the following decision algorithms best integrates the Direct antiglobulin test (DAT), maternal–infant blood group information, peripheral smear morphology, enzyme assays, and patterns of Coombs-negative hemolysis to differentiate etiologies in this neonate?\n\nA. Begin with maternal–infant ABO and Rhesus D (RhD) typing. If incompatible, diagnose hemolytic disease of the newborn and treat; if compatible, proceed directly to enzyme assays (glucose-6-phosphate dehydrogenase and pyruvate kinase). Order the Direct antiglobulin test (DAT) only if enzyme assays are normal. Use the peripheral smear only if DAT is positive.\n\nB. Begin with the Direct antiglobulin test (DAT). If DAT is positive, use maternal–infant ABO and Rhesus D (RhD) typing to categorize: mother blood group O with infant A or B and weak DAT suggests ABO hemolytic disease of the newborn; RhD-negative mother with RhD-positive infant and strong DAT suggests RhD hemolytic disease of the newborn; if ABO/RhD are compatible, perform an elution study from infant red blood cells and maternal antibody screen to identify minor blood group antibodies (for example, Kell, Duffy, Kidd). If DAT is negative, evaluate the peripheral smear: spherocytes suggest hereditary spherocytosis (confirm with eosin-5-maleimide binding or osmotic fragility testing); bite or blister cells suggest oxidant injury (obtain glucose-6-phosphate dehydrogenase assay, with caution for falsely normal results during high reticulocytosis); echinocytes with hemolysis suggest pyruvate kinase deficiency (confirm with pyruvate kinase assay); schistocytes suggest microangiopathic hemolysis (evaluate coagulation studies). Use enzyme assays to confirm suspected enzyme defects.\n\nC. Begin with the indirect antiglobulin test (indirect Coombs). If negative, exclude immune hemolysis. If the peripheral smear shows spherocytes, diagnose ABO hemolytic disease of the newborn. If the smear is normal, order glucose-6-phosphate dehydrogenase and pyruvate kinase assays to identify enzyme deficiencies. Use maternal–infant blood group only to assess transfusion compatibility.\n\nD. Begin with total serum bilirubin. If bilirubin is elevated above the exchange transfusion threshold, order glucose-6-phosphate dehydrogenase assay first; if bilirubin is below threshold, order the Direct antiglobulin test (DAT). If DAT is positive, diagnose RhD hemolytic disease of the newborn regardless of maternal–infant blood group; if DAT is negative, treat supportively without further testing.\n\nSelect one option.",
            "solution": "### Problem Validation\n\n**Step 1: Extract Givens**\n\nThe problem provides the following clinical scenario and established facts:\n*   **Clinical Presentation:** A term neonate at day $2$ of life presents with jaundice, pallor, and tachycardia.\n*   **Laboratory Data:** Anemia with elevated reticulocytes and predominantly unconjugated hyperbilirubinemia. These findings are consistent with active hemolysis.\n*   **Fact 1 (Role of DAT):** The Direct antiglobulin test ($DAT$) detects immunoglobulins or complement on red blood cells ($RBCs$). A positive $DAT$ indicates immune-mediated hemolysis. A negative $DAT$ suggests non-immune causes.\n*   **Fact 2 (Immune Hemolysis - Major Groups):** Maternal placental-crossing antibodies are typically Immunoglobulin G ($IgG$). $ABO$ incompatibility (most often mother group $O$, infant $A$ or $B$) can cause a weakly positive $DAT$. Rhesus $D$ ($RhD$) disease ($RhD$-negative mother, $RhD$-positive infant) often causes a strongly positive $DAT$.\n*   **Fact 3 (Non-Immune Hemolysis):** In $DAT$-negative hemolysis, peripheral smear morphology is a key discriminator:\n    *   Spherocytes suggest membrane defects (e.g., hereditary spherocytosis).\n    *   Bite or blister cells suggest oxidant injury (e.g., glucose-$6$-phosphate dehydrogenase ($G6PD$) deficiency).\n    *   Schistocytes suggest mechanical fragmentation (e.g., disseminated intravascular coagulation).\n    *   Echinocytes suggest pyruvate kinase ($PK$) deficiency.\n*   **Fact 4 (Enzyme Assays):** Enzyme activity assays (e.g., for $G6PD$, $PK$) are used for confirmation, but can yield falsely normal results during acute hemolytic episodes due to high reticulocyte counts.\n*   **Fact 5 (Immune Hemolysis - Minor Groups):** If the $DAT$ is positive but $ABO$ and $RhD$ blood groups are compatible, minor blood group antibodies (e.g., Kell, Duffy, Kidd) should be investigated via elution testing and maternal antibody screening.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem statement is evaluated against the validation criteria:\n*   **Scientifically Grounded:** The problem is firmly rooted in the established principles of neonatology and hematopathology. The clinical presentation, laboratory findings, and the \"well-established facts\" provided are all standard, textbook medical knowledge for the diagnostic workup of neonatal hemolysis.\n*   **Well-Posed:** The problem is well-posed. It asks for the most appropriate diagnostic algorithm based on a set of consistent and sufficient facts. A single, most logical pathway can be constructed from these facts.\n*   **Objective:** The language is clinical, precise, and objective. It presents a factual scenario and asks for a logical synthesis of given principles.\n\nThe problem statement exhibits no discernible flaws such as scientific unsoundness, ambiguity, contradiction, or infeasibility. It is a valid clinical reasoning problem.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. A solution will be derived by constructing the most logical diagnostic algorithm from the provided principles and then evaluating each option against this standard.\n\n### Derivation of the Optimal Diagnostic Pathway\n\nThe clinical and laboratory picture is one of neonatal hemolytic anemia. The fundamental diagnostic challenge is to identify the underlying cause. Based on the provided facts, the most rational approach must first distinguish between the two major categories of hemolysis: immune and non-immune.\n\n1.  **Primary Discriminator:** Fact $1$ establishes the Direct Antiglobulin Test ($DAT$) as the definitive test to separate immune from non-immune etiologies. Therefore, the algorithm must begin with the $DAT$.\n\n2.  **Positive DAT Pathway (Immune Hemolysis):** If the $DAT$ is positive, the cause is immune-mediated. The subsequent steps, as outlined in Facts $2$ and $5$, should be to identify the specific antibody.\n    *   Determine maternal and infant $ABO$ and $RhD$ blood types.\n    *   If there is $ABO$ or $RhD$ incompatibility, these are the most likely causes ($ABO$ disease is often associated with a weakly positive $DAT$; $RhD$ disease with a strongly positive $DAT$).\n    *   If the major blood groups are compatible despite a positive $DAT$, investigate for minor blood group antibodies using elution tests on the infant's $RBCs$ and a maternal antibody screen.\n\n3.  **Negative DAT Pathway (Non-Immune Hemolysis):** If the $DAT$ is negative, immune hemolysis is unlikely. The investigation must proceed to non-immune causes.\n    *   Fact $3$ indicates that the peripheral blood smear is the next crucial step, as specific $RBC$ morphologies point toward different underlying pathophysiologies.\n    *   Based on the smear findings, targeted confirmatory testing is initiated:\n        *   **Spherocytes** lead to investigation for $RBC$ membrane defects (e.g., hereditary spherocytosis).\n        *   **Bite/Blister cells** lead to investigation for oxidant injury, primarily by assaying for $G6PD$ deficiency (keeping in mind the caveat from Fact $4$).\n        *   **Echinocytes** lead to investigation for enzymopathies like pyruvate kinase deficiency.\n        *   **Schistocytes** suggest microangiopathic hemolysis, prompting a workup for conditions like disseminated intravascular coagulation.\n\nThis derived pathway is the most efficient and logically sound algorithm based on the problem's premises.\n\n### Option-by-Option Analysis\n\n**A. Begin with maternal–infant ABO and Rhesus D (RhD) typing. If incompatible, diagnose hemolytic disease of the newborn and treat; if compatible, proceed directly to enzyme assays (glucose-6-phosphate dehydrogenase and pyruvate kinase). Order the Direct antiglobulin test (DAT) only if enzyme assays are normal. Use the peripheral smear only if DAT is positive.**\n\nThis algorithm is illogical. It fails to use the $DAT$ as the primary branching test to distinguish immune from non-immune causes. It incorrectly assumes compatibility in $ABO/RhD$ rules out immune hemolysis (ignoring minor antibodies) and proceeds inappropriately to enzyme assays. Furthermore, it completely misuses the peripheral smear, which is most valuable in the $DAT$-negative setting, not the $DAT$-positive one.\nVerdict: **Incorrect**.\n\n**B. Begin with the Direct antiglobulin test (DAT). If DAT is positive, use maternal–infant ABO and Rhesus D (RhD) typing to categorize: mother blood group O with infant A or B and weak DAT suggests ABO hemolytic disease of the newborn; RhD-negative mother with RhD-positive infant and strong DAT suggests RhD hemolytic disease of the newborn; if ABO/RhD are compatible, perform an elution study from infant red blood cells and maternal antibody screen to identify minor blood group antibodies (for example, Kell, Duffy, Kidd). If DAT is negative, evaluate the peripheral smear: spherocytes suggest hereditary spherocytosis (confirm with eosin-5-maleimide binding or osmotic fragility testing); bite or blister cells suggest oxidant injury (obtain glucose-6-phosphate dehydrogenase assay, with caution for falsely normal results during high reticulocytosis); echinocytes with hemolysis suggest pyruvate kinase deficiency (confirm with pyruvate kinase assay); schistocytes suggest microangiopathic hemolysis (evaluate coagulation studies). Use enzyme assays to confirm suspected enzyme defects.**\n\nThis option perfectly mirrors the logically derived optimal pathway. It correctly starts with the $DAT$. The subsequent steps for both the positive $DAT$ branch (evaluating major and minor blood groups) and the negative $DAT$ branch (using the peripheral smear to guide further testing for membrane defects, enzymopathies, and microangiopathies) are all correct and in the proper sequence, incorporating all the nuances from the provided facts.\nVerdict: **Correct**.\n\n**C. Begin with the indirect antiglobulin test (indirect Coombs). If negative, exclude immune hemolysis. If the peripheral smear shows spherocytes, diagnose ABO hemolytic disease of the newborn. If the smear is normal, order glucose-6-phosphate dehydrogenase and pyruvate kinase assays to identify enzyme deficiencies. Use maternal–infant blood group only to assess transfusion compatibility.**\n\nThis option contains multiple fundamental errors. First, it begins with the *indirect* antiglobulin test on the mother, whereas the primary test for ongoing hemolysis in the neonate is the *direct* test ($DAT$) on the neonate's cells. Second, it incorrectly states that spherocytes are diagnostic for $ABO$ hemolytic disease; they are the classic finding in hereditary spherocytosis, a non-immune condition (Fact $3$). This conflates two distinct etiologies.\nVerdict: **Incorrect**.\n\n**D. Begin with total serum bilirubin. If bilirubin is elevated above the exchange transfusion threshold, order glucose-6-phosphate dehydrogenase assay first; if bilirubin is below threshold, order the Direct antiglobulin test (DAT). If DAT is positive, diagnose RhD hemolytic disease of the newborn regardless of maternal–infant blood group; if DAT is negative, treat supportively without further testing.**\n\nThis algorithm is clinically unsound and dangerous. The choice of diagnostic test should not be dictated by the severity of the bilirubin level but by diagnostic logic. Ordering a $G6PD$ assay first in severe hyperbilirubinemia is arbitrary and could miss a severe immune cause. Critically, diagnosing $RhD$ disease based on a positive $DAT$ alone, without blood typing, is a major error (Fact $2$). Finally, ceasing investigation after a negative $DAT$ constitutes negligence, as it fails to diagnose potentially serious non-immune causes of hemolysis which require specific management.\nVerdict: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The prevention of HDN in future pregnancies is a cornerstone of modern obstetrics and transfusion medicine. This final practice places you in the role of a laboratory professional tasked with preventing maternal sensitization after the delivery of an RhD-positive infant to an RhD-negative mother. You will use data from a Kleihauer-Betke test to quantify the volume of the fetal-maternal hemorrhage and calculate the precise dose of Rhesus immune globulin (RhIg) required, demonstrating a critical application of laboratory data to clinical intervention .",
            "id": "4379650",
            "problem": "A Rhesus factor negative ($\\text{Rh}^-$) mother has delivered a Rhesus factor positive ($\\text{Rh}^+$) infant. To prevent hemolytic disease of the newborn in future pregnancies, Rhesus immune globulin (RhIg) prophylaxis is required postpartum. The laboratory performs a Kleihauer–Betke acid elution test (Kleihauer–Betke) on a maternal peripheral blood smear and counts $n_{\\text{total}} = 2000$ erythrocytes, of which $n_{\\text{fetal}} = 78$ retain fetal hemoglobin, consistent with fetal-origin red blood cells. A separate dye-dilution measurement determines the maternal blood volume to be $V_{\\text{m}} = 5.20\\,\\text{L}$.\n\nStarting from first principles that:\n- the Kleihauer–Betke count yields a statistically unbiased estimate of the fraction of fetal-origin red cells mixed in the maternal circulation when sampling is random,\n- the fraction of fetal-origin red cells in the sample equals the fraction of fetal whole blood volume mixed in the maternal whole blood volume under the assumption of uniform mixing,\n- each $300\\,\\mu\\text{g}$ vial of RhIg neutralizes the sensitizing potential of $30\\,\\text{mL}$ of fetal whole blood,\n\nderive the fetal whole blood volume in the maternal circulation and determine the smallest integer number of RhIg vials that fully covers this volume.\n\nInstructions:\n- Treat $1\\,\\text{L} = 1000\\,\\text{mL}$.\n- Express the intermediate fetal whole blood volume in milliliters, rounded to four significant figures.\n- For the final dose, apply the clinical rule of rounding up to the next whole vial.\n- Provide only the integer number of vials as your final answer, with no units in the final answer box.",
            "solution": "The problem is assessed to be valid as it is scientifically grounded, well-posed, and objective. It describes a standard clinical calculation in immunohematology without containing any scientific flaws, ambiguities, or contradictions.\n\nThe solution is derived from the first principles and data provided.\n\nFirst, we determine the fraction of fetal red blood cells (RBCs) in the maternal circulation, denoted as $f_{\\text{cells}}$. This fraction is estimated from the Kleihauer–Betke test result, which is the ratio of counted fetal RBCs, $n_{\\text{fetal}}$, to the total number of RBCs counted, $n_{\\text{total}}$.\nGiven:\n$n_{\\text{fetal}} = 78$\n$n_{\\text{total}} = 2000$\n\nThe fraction is calculated as:\n$$f_{\\text{cells}} = \\frac{n_{\\text{fetal}}}{n_{\\text{total}}} = \\frac{78}{2000} = 0.039$$\n\nNext, we apply the principle that the fraction of fetal RBCs in the sample is equal to the fraction of fetal whole blood volume, $V_{\\text{f}}$, within the maternal whole blood volume, $V_{\\text{m}}$.\n$$\\frac{V_{\\text{f}}}{V_{\\text{m}}} = f_{\\text{cells}}$$\nWe can rearrange this equation to solve for the volume of fetal whole blood that has entered the maternal circulation:\n$$V_{\\text{f}} = V_{\\text{m}} \\times f_{\\text{cells}}$$\n\nThe maternal blood volume is given as $V_{\\text{m}} = 5.20\\,\\text{L}$. To maintain consistent units with the RhIg coverage volume (given in milliliters), we convert $V_{\\text{m}}$ to milliliters ($\\text{mL}$) using the provided conversion factor $1\\,\\text{L} = 1000\\,\\text{mL}$.\n$$V_{\\text{m}} = 5.20\\,\\text{L} \\times \\frac{1000\\,\\text{mL}}{1\\,\\text{L}} = 5200\\,\\text{mL}$$\n\nNow we can calculate the fetal whole blood volume, $V_{\\text{f}}$:\n$$V_{\\text{f}} = 5200\\,\\text{mL} \\times 0.039 = 202.8\\,\\text{mL}$$\nThe problem instructs to round this intermediate value to four significant figures. The calculated value $202.8\\,\\text{mL}$ already has exactly four significant figures, so no further rounding is necessary at this stage.\n\nThe final step is to determine the number of Rhesus immune globulin (RhIg) vials required to neutralize this volume of fetal blood. Each $300\\,\\mu\\text{g}$ vial of RhIg is stated to neutralize the sensitizing potential of $V_{\\text{vial_coverage}} = 30\\,\\text{mL}$ of fetal whole blood.\n\nThe number of vials required, $N_{\\text{vials}}$, is calculated by dividing the total fetal blood volume, $V_{\\text{f}}$, by the volume neutralized per vial, $V_{\\text{vial_coverage}}$.\n$$N_{\\text{vials, raw}} = \\frac{V_{\\text{f}}}{V_{\\text{vial_coverage}}} = \\frac{202.8\\,\\text{mL}}{30\\,\\text{mL}} = 6.76$$\n\nThe problem specifies that the clinical rule is to round up to the next whole vial to ensure full coverage. This is mathematically equivalent to applying the ceiling function to the calculated raw number of vials.\n$$N_{\\text{vials, final}} = \\lceil N_{\\text{vials, raw}} \\rceil = \\lceil 6.76 \\rceil$$\nTherefore, the smallest integer number of vials that fully covers the fetal-maternal hemorrhage is:\n$$N_{\\text{vials, final}} = 7$$",
            "answer": "$$\\boxed{7}$$"
        }
    ]
}